Amino Acid Infusion in Kidney Transplant Recipients

Launched by UNIVERSITY HOSPITAL, MARTIN · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of amino acid infusion in patients who have recently received a kidney transplant. Specifically, the study aims to see how this treatment might improve kidney function and reduce complications in the early days after the transplant. Researchers want to understand how amino acids, which are the building blocks of proteins, can help with recovery and overall health in kidney transplant recipients.

To participate in the trial, individuals must be adults aged 18 or older who are receiving their first kidney transplant from either a deceased or living donor. They should not have any allergies to amino acids and need to be in stable condition after their transplant. However, people who require immediate dialysis after the transplant or have certain serious health conditions, like severe liver disease or uncontrolled infections, won’t be eligible. Those who join the study will help researchers learn more about how amino acid infusion can impact recovery and health following a kidney transplant, potentially leading to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (≥18 years) undergoing deceased or living donor kidney transplantation
• • First-time kidney transplant recipients
• • No known allergy or contraindication to amino acids
• • Stable hemodynamic status post-transplant
• • Signed informed consent
• Exclusion Criteria:
• • Patients requiring immediate dialysis post-transplant
• • Multi-organ transplant recipients
• • Severe hepatic dysfunction (Child-Pugh C)
• • Uncontrolled infection or sepsis
• • Malignancy within the past 5 years (except non-melanoma skin cancer)
• • Prior participation in conflicting clinical trials